CL2014001055A1 - Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso. - Google Patents

Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.

Info

Publication number: CL2014001055A1
Authority: CL; Chile
Prior art keywords: tnf; interleukin; binds; vector; nucleic acid
Prior art date: 2011-10-24

Application number

CL2014001055A

Other languages

English (en)

Inventor

Chung-Ming Hsieh

Jennifer Perez

Lorenzo Benatuil

Yuliya Kutskova

John Memmott

Suju Zhong

Lucia Eaton

Margaret Hugunin

Alyssa Brito

Anca Clabbers

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-24

Filing date

2014-04-24

Publication date

2014-08-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47144148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001055(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-24 Application filed by Abbvie Inc filed Critical Abbvie Inc

2014-08-18 Publication of CL2014001055A1 publication Critical patent/CL2014001055A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Pathology (AREA)

CL2014001055A 2011-10-24 2014-04-24 Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso. CL2014001055A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161550619P	2011-10-24	2011-10-24

Publications (1)

Publication Number	Publication Date
CL2014001055A1 true CL2014001055A1 (es)	2014-08-18

Family

ID=47144148

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001055A CL2014001055A1 (es)	2011-10-24	2014-04-24	Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.

Country Status (26)

Country	Link
US (2)	US9655964B2 (es)
EP (1)	EP2771361A1 (es)
JP (1)	JP6121432B2 (es)
KR (1)	KR20140084254A (es)
CN (1)	CN104185641A (es)
AR (1)	AR088514A1 (es)
AU (1)	AU2012328917B2 (es)
BR (1)	BR112014009810A2 (es)
CA (1)	CA2853114A1 (es)
CL (1)	CL2014001055A1 (es)
CO (1)	CO7020874A2 (es)
CR (1)	CR20140224A (es)
DO (1)	DOP2014000084A (es)
EC (1)	ECSP14001260A (es)
GT (1)	GT201400077A (es)
HK (1)	HK1200321A1 (es)
IL (1)	IL232207A0 (es)
MX (1)	MX2014004980A (es)
PE (1)	PE20142245A1 (es)
PH (1)	PH12014500903A1 (es)
RS (1)	RS20140202A1 (es)
RU (1)	RU2014121043A (es)
SG (1)	SG11201401796SA (es)
TW (1)	TW201323441A (es)
UY (1)	UY34410A (es)
WO (1)	WO2013063110A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY159837A (en)	2009-08-29	2017-02-15	Abbvie Inc	Therapeutic dll4 binding proteins
SG183872A1 (en)	2010-03-02	2012-11-29	Abbvie Inc	Therapeutic dll4 binding proteins
MX2012013490A (es)	2010-05-20	2013-01-29	Ablynx Nv	Materiales biologicos relacionados con her3.
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
AR083495A1 (es)	2010-10-22	2013-02-27	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles
AR084210A1 (es) *	2010-12-08	2013-05-02	Abbott Lab	PROTEINAS DE UNION AL TNF-a
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
BR112014009799A2 (pt)	2011-10-24	2017-06-13	Abbvie Inc	imunoligantes dirigidos conra tnf
US9217042B2 (en) *	2012-10-23	2015-12-22	Abbott Cardiovascular Systems Inc.	Method of reducing MACE in diabetic patients subsequent to stent placement
TW202210507A (zh)	2012-11-01	2022-03-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
AU2014227664A1 (en) *	2013-03-15	2015-09-24	Abbvie Inc.	Dual specific binding proteins directed against TNFalpha
EP3072905B1 (en) *	2013-11-18	2020-08-19	Shanghai Hengrui Pharmaceutical Co., Ltd.	Il-17a binding agent and uses thereof
EP3560954B1 (en)	2014-04-03	2021-08-04	IGM Biosciences, Inc.	Modified j-chain
US20160002326A1 (en) *	2014-06-10	2016-01-07	Abbvie Inc.	Compositions and methods for treating rheumatoid arthritis
US20160000936A1 (en)	2014-06-10	2016-01-07	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
JP6663910B2 (ja) *	2014-08-26	2020-03-13	アムジェンケー・エー，インコーポレイテッド	抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法
SG11201701423RA (en)	2014-09-03	2017-03-30	Boehringer Ingelheim Int	Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es)	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
GB201500463D0 (en)	2015-01-12	2015-02-25	Cresendo Biolog Ltd	Therapeutic molecules
US10689449B2 (en)	2015-01-20	2020-06-23	Igm Biosciences, Inc.	Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
FI3355913T3 (fi)	2015-09-30	2024-12-02	Igm Biosciences Inc	Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä
DK3356401T3 (da)	2015-09-30	2020-09-07	Igm Biosciences Inc	Bindingsmolekyler med modificeret j-kæde
CA3000779A1 (en) *	2015-10-05	2017-04-13	Morphosys Ag	Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
UA125611C2 (uk)	2015-12-14	2022-05-04	Макродженікс, Інк.	Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
GB201522391D0 (en) *	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibody molecules
WO2017132457A1 (en) *	2016-01-28	2017-08-03	Janssen Biotech, Inc.	BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE
RU2680011C2 (ru)	2016-04-29	2019-02-14	Закрытое Акционерное Общество "Биокад"	Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
EP3901162A1 (en)	2016-06-02	2021-10-27	AbbVie Inc.	Glucocorticoid receptor agonist and immunoconjugates thereof
EP3538141A4 (en)	2016-11-10	2020-07-15	Merck Sharp & Dohme Corp.	LIGAND ILT3
AU2018335231B2 (en) *	2017-09-22	2022-03-24	F. Hoffmann-La Roche Ag	Multivalent mono- or bispecific recombinant antibodies for analytic purpose
BR112020010694A2 (pt)	2017-12-01	2020-11-10	Abbvie Inc.	agonista de receptor de glicocorticoides e imunoconjugados do mesmo
MA54857A (fr)	2019-01-31	2021-12-08	Numab Therapeutics AG	Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
WO2020180967A1 (en) *	2019-03-04	2020-09-10	Amgen Inc.	In vivo reversibility of high molecular weight species
US12527879B2 (en)	2019-06-04	2026-01-20	Academia Sinica	Ligands targeted to epidermal growth factor receptors and compositions for use in treating tumors
WO2021168274A1 (en)	2020-02-21	2021-08-26	Silverback Therapeutics, Inc.	Nectin-4 antibody conjugates and uses thereof
CA3177830A1 (en)	2020-05-13	2021-11-18	Maria BECONI	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021300362A1 (en)	2020-07-01	2023-02-23	ARS Pharmaceuticals, Inc.	Anti-ASGR1 antibody conjugates and uses thereof
CN112375149B (zh) *	2020-10-30	2023-04-18	沣潮医药科技（上海）有限公司	Ace2免疫融合蛋白及其应用
CA3235096A1 (en)	2021-11-17	2023-05-25	Disc Medicine, Inc.	Methods for treating anemia of kidney disease
WO2025049345A1 (en)	2023-08-25	2025-03-06	Proteologix Us Inc.	Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
DE3631229A1 (de) *	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5006309A (en)	1988-04-22	1991-04-09	Abbott Laboratories	Immunoassay device with liquid transfer between wells by washing
US5089424A (en)	1988-06-14	1992-02-18	Abbott Laboratories	Method and apparatus for heterogeneous chemiluminescence assay
SE462454B (sv)	1988-11-10	1990-06-25	Pharmacia Ab	Maetyta foer anvaendning i biosensorer
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US5063081A (en)	1988-11-14	1991-11-05	I-Stat Corporation	Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5135875A (en)	1990-08-15	1992-08-04	Abbott Laboratories	Protein precipitation reagent
CA2048302A1 (en)	1990-08-15	1992-02-16	Victoria P. Meucci	Solubilization reagent for biological test samples
CA2069530A1 (en)	1991-06-03	1992-12-04	Cass J. Grandone	Reagent pack for immunoassays
DE69332988T2 (de)	1992-03-30	2004-05-19	Abbott Laboratories, Abbott Park	Reagenzien zum Nachweis und zur Quantifizierung von Thyroxin in flüssigen Proben
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en)	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
CN1300173C (zh)	1996-02-09	2007-02-14	艾博特生物技术有限公司	结合人TNFα的人抗体
NZ516848A (en)	1997-06-20	2004-03-26	Ciphergen Biosystems Inc	Retentate chromatography apparatus with applications in biology and medicine
AU3463699A (en)	1998-04-03	1999-10-25	Phylos, Inc.	Addressable protein arrays
US6406921B1 (en)	1998-07-14	2002-06-18	Zyomyx, Incorporated	Protein arrays for high-throughput screening
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
AU4025300A (en)	1999-03-24	2000-10-09	Packard Bioscience Company	Continuous porous matrix arrays
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
MXPA02010011A (es)	2000-04-11	2003-04-25	Genentech Inc	Anticuerpos multivalentes y usos para los mismos.
JP4955185B2 (ja)	2000-06-29	2012-06-20	アボット・ラボラトリーズ	二重特異性抗体ならびに作製方法および使用方法
US7419821B2 (en)	2002-03-05	2008-09-02	I-Stat Corporation	Apparatus and methods for analyte measurement and immunoassay
DK1523496T3 (da)	2002-07-18	2011-10-17	Merus B V	Rekombinant fremstilling af blanding af antistoffer
US20040018577A1 (en)	2002-07-29	2004-01-29	Emerson Campbell John Lewis	Multiple hybrid immunoassay
ES2347239T3 (es)	2002-12-02	2010-10-27	Amgen Fremont Inc.	Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
CN1942588B (zh)	2003-03-05	2013-06-12	海洋酶公司	可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
NZ544618A (en)	2003-06-16	2009-02-28	Celltech R & D Inc	Antibodies specific for sclerostin and methods for increasing bone mineralization
AU2004280333A1 (en)	2003-08-22	2005-04-21	Medimmune, Llc	Humanization of antibodies
US7682833B2 (en)	2003-09-10	2010-03-23	Abbott Point Of Care Inc.	Immunoassay device with improved sample closure
US7723099B2 (en)	2003-09-10	2010-05-25	Abbott Point Of Care Inc.	Immunoassay device with immuno-reference electrode
EP1769003A1 (en)	2004-07-06	2007-04-04	Bioren, Inc.	HIGH AFFINITY ANTI-TNF-alpha ANTIBODIES AND METHOD
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US7883855B2 (en)	2006-07-21	2011-02-08	Abbott Laboratories	Immunosuppressant drug extraction reagent for immunoassays
EP2097450A2 (en)	2006-11-10	2009-09-09	Amgen Inc.	Antibody-based diagnostics and therapeutics
WO2008133722A2 (en)	2006-11-10	2008-11-06	Ucb Pharma S.A.	Anti human sclerostin antibodies
EA018204B1 (ru)	2007-03-20	2013-06-28	Эли Лилли Энд Компани	Антитела против склеростина
US7906293B2 (en)	2007-04-09	2011-03-15	Abbott Laboratories	Acridinium phenyl esters useful in the analysis of biological
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101970655B (zh)	2008-01-15	2014-03-05	Abbvie公司	改良哺乳动物表达载体及其用途
JP2011523853A (ja)	2008-06-03	2011-08-25	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリン及びその使用
RU2015132478A (ru)	2009-03-05	2015-12-10	Эббви Инк.	Связывающие il-17 белки
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012011629A (es) *	2010-04-07	2013-03-05	Abbvie Inc	Proteinas de union a tnf-alfa.
BR112013002578A2 (pt) *	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
AR084210A1 (es)	2010-12-08	2013-05-02	Abbott Lab	PROTEINAS DE UNION AL TNF-a
BR112014009799A2 (pt)	2011-10-24	2017-06-13	Abbvie Inc	imunoligantes dirigidos conra tnf
SG11201401791WA (en)	2011-10-24	2014-08-28	Abbvie Inc	Immunobinders directed against sclerostin

2012
- 2012-10-24 WO PCT/US2012/061686 patent/WO2013063110A1/en not_active Ceased
- 2012-10-24 JP JP2014538926A patent/JP6121432B2/ja active Active
- 2012-10-24 EP EP12783474.5A patent/EP2771361A1/en not_active Withdrawn
- 2012-10-24 US US13/659,666 patent/US9655964B2/en active Active
- 2012-10-24 TW TW101139328A patent/TW201323441A/zh unknown
- 2012-10-24 CN CN201280064228.6A patent/CN104185641A/zh active Pending
- 2012-10-24 PH PH1/2014/500903A patent/PH12014500903A1/en unknown
- 2012-10-24 HK HK15100713.9A patent/HK1200321A1/xx unknown
- 2012-10-24 RS RS20140202A patent/RS20140202A1/sr unknown
- 2012-10-24 SG SG11201401796SA patent/SG11201401796SA/en unknown
- 2012-10-24 CA CA2853114A patent/CA2853114A1/en not_active Abandoned
- 2012-10-24 AR ARP120103979A patent/AR088514A1/es unknown
- 2012-10-24 MX MX2014004980A patent/MX2014004980A/es unknown
- 2012-10-24 AU AU2012328917A patent/AU2012328917B2/en not_active Ceased
- 2012-10-24 BR BR112014009810A patent/BR112014009810A2/pt not_active IP Right Cessation
- 2012-10-24 PE PE2014000606A patent/PE20142245A1/es not_active Application Discontinuation
- 2012-10-24 KR KR1020147013797A patent/KR20140084254A/ko not_active Withdrawn
- 2012-10-24 RU RU2014121043/10A patent/RU2014121043A/ru not_active Application Discontinuation
- 2012-10-24 UY UY0001034410A patent/UY34410A/es not_active Application Discontinuation
2013
- 2013-11-18 US US14/082,502 patent/US20140079705A1/en not_active Abandoned
2014
- 2014-04-23 IL IL232207A patent/IL232207A0/en unknown
- 2014-04-24 GT GT201400077A patent/GT201400077A/es unknown
- 2014-04-24 DO DO2014000084A patent/DOP2014000084A/es unknown
- 2014-04-24 CL CL2014001055A patent/CL2014001055A1/es unknown
- 2014-05-14 CR CR20140224A patent/CR20140224A/es unknown
- 2014-05-19 EC ECIEPI20141260A patent/ECSP14001260A/es unknown
- 2014-05-22 CO CO14110752A patent/CO7020874A2/es unknown

Also Published As

Publication number	Publication date
CN104185641A (zh)	2014-12-03
BR112014009810A2 (pt)	2017-04-25
US20140079705A1 (en)	2014-03-20
ECSP14001260A (es)	2015-07-31
CA2853114A1 (en)	2013-05-02
SG11201401796SA (en)	2014-10-30
GT201400077A (es)	2014-12-23
HK1200321A1 (en)	2015-08-07
JP2015502145A (ja)	2015-01-22
JP6121432B2 (ja)	2017-04-26
US20140161804A1 (en)	2014-06-12
AU2012328917B2 (en)	2017-05-25
KR20140084254A (ko)	2014-07-04
RS20140202A1 (sr)	2014-10-31
US9655964B2 (en)	2017-05-23
AU2012328917A1 (en)	2014-05-22
RU2014121043A (ru)	2015-12-10
TW201323441A (zh)	2013-06-16
EP2771361A1 (en)	2014-09-03
AR088514A1 (es)	2014-06-18
PH12014500903A1 (en)	2014-06-09
PE20142245A1 (es)	2015-01-22
CO7020874A2 (es)	2014-08-11
IL232207A0 (en)	2014-06-30
WO2013063110A1 (en)	2013-05-02
MX2014004980A (es)	2014-09-11
UY34410A (es)	2013-05-31
CR20140224A (es)	2014-09-03
DOP2014000084A (es)	2014-09-15

Publication	Publication Date	Title
CL2014001055A1 (es)	2014-08-18	Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.
CL2014001054A1 (es)	2014-09-05	Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra.
CL2013000566A1 (es)	2014-01-24	Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013001625A1 (es)	2014-02-21	Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
CL2012003610A1 (es)	2013-05-17	Proteina de union multivalente y multiespecífica que se une al factor de necrosis tumoral (tnf) y al inductor de apoptosis debil relacionado con el factor de necrosis tumoral (tweak); conjugado de union de dicha proteína; acido nucleico que la codifica; vector y célula que comprenden dicho acido nucleico; metodo para producir dicha proteína; composicion farmacéutica que comprende dicha proteína
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2013001831A1 (es)	2013-11-08	Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CL2013000074A1 (es)	2013-12-06	Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2014000631A1 (es)	2014-09-26	Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013003336A1 (es)	2014-06-06	Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico
PH12020551907A1 (en)	2021-06-14	Antagonizing cd73 antibody
CL2014000699A1 (es)	2014-09-12	Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
CL2013001210A1 (es)	2013-11-08	Proteina de union multivalente que une ya sea a tnf y pge2 o vegf y dll4; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CL2012002783A1 (es)	2013-07-12	Proteinas de unión humanizada que se une al factor de necrosis tumoral alfa humano (tnf-alfa); composicion para liberar una proteina que se une a tnf-alfa; construccionde una proteina que puede unirse al tnf-alfa; acido nucleico, vector y celula huesped que comprenden dicha construccion.
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2010001425A1 (es)	2011-04-08	Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
CL2013001279A1 (es)	2014-03-07	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
EA201492101A1 (ru)	2015-04-30	Антитела против fcrn
CL2013001403A1 (es)	2014-08-08	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
MX2015008446A (es)	2016-10-26	Composiciones de proteinas de union multivalentes.
CL2012003093A1 (es)	2013-03-22	Anticuerpo aislado multivalente que tiene al menos dos dominios de union a receptores para dos diferentes sitios de union de un receptor diana lrp6 que inhiben una via canonica de transduccion de señal wnt; anticuerpo aislado biparatopico que une lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; metodo de obtencion de dicho anticuerpo; y su uso para tratar cancer.
CL2011002567A1 (es)	2012-02-24	Anticuerpo antifactor de necrosis tumoral alfa (tnf-a) o fragmento de union del mismo; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno inmune.
MX374682B (es)	2025-03-06	Moléculas de unión a 4-1bb.
CL2008002444A1 (es)	2009-09-04	Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
PH12014502527B1 (en)	2020-11-11	St2 antigen binding proteins